
Oncology NEWS International
- Oncology NEWS International Vol 6 No 12
- Volume 6
- Issue 12
Patients Sought for New Trial of Adoptive Immunotherapy
CHICAGO-Researchers from three midwestern centers are seeking patients with leukemia, lymphoma, or multiple myeloma who have relapsed after an allogeneic stem cell transplant for a new trial of adoptive immunotherapy.
CHICAGOResearchers from three midwestern centers are seeking patients with leukemia, lymphoma, or multiple myeloma who have relapsed after an allogeneic stem cell transplant for a new trial of adoptive immunotherapy.
The concept of the study is that lymphocyte infusions from the original donor may induce remission. However, this approach may also be complicated by graft-versus-host disease (GVHD).
The researchers will attempt remission induction by infusion of IL-2-activated lymphocytes transduced with the herpes simplex thymidine kinase (HSTK) gene. If severe GVHD occurs, the infused lymphocytes will be killed by adminis-tration of the prodrug ganciclovir (Cytovene).
For referrals, contact Dr. Richard Burt at Northwestern University (312-908-5400), Dr. William Drobyski or Dr. William Burns at the Medical College of Wisconsin, Milwaukee (414-257-5452), or Dr. Charles Link at the Human Gene Therapy Research Institute, Des Moines, Iowa (515-241-8790).
Articles in this issue
over 28 years ago
Team-Based Approach to Managed Specialty Careover 28 years ago
Children’s Art Project at M.D. Andersonover 28 years ago
Office of Cancer Survivorship Grants Awards for First 20 Studiesover 28 years ago
Laparoscopic Colectomy May Prove Equivalent to Open Surgeryover 28 years ago
Advice on Negotiating BMT Service Contractsover 28 years ago
Komen Debuts New Websites on Breast Cancerover 28 years ago
‘MDs Too Often Fail to Give Adequate Analgesic Doses’over 28 years ago
Breach of Fiduciary Duty-How to Defend Against Itover 28 years ago
Survivors Help Women Deal With Breast Cancer Diagnosisover 28 years ago
University of Utah’s Huntsman Cancer Institute Joins NCCNNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.























































